Advanced search

Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation

Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
De Keyser, Filip, Dominique Baeten, Filip Van Den Bosch, Elli Kruithof, Herman Mielants, and Eric Veys. 2003. “Infliximab in Patients Who Have Spondyloarthropathy: Clinical Efficacy, Safety and Biological Immunomodulation.” Rheumatic Diseases Clin. N. Am. 29: 463–479.
APA
De Keyser, F., Baeten, D., Van Den Bosch, F., Kruithof, E., Mielants, H., & Veys, E. (2003). Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation. Rheumatic diseases Clin. N. Am., 29, 463–479.
Vancouver
1.
De Keyser F, Baeten D, Van Den Bosch F, Kruithof E, Mielants H, Veys E. Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation. Rheumatic diseases Clin. N. Am. 2003;29:463–79.
MLA
De Keyser, Filip, Dominique Baeten, Filip Van Den Bosch, et al. “Infliximab in Patients Who Have Spondyloarthropathy: Clinical Efficacy, Safety and Biological Immunomodulation.” Rheumatic diseases Clin. N. Am. 29 (2003): 463–479. Print.
@article{209164,
  author       = {De Keyser, Filip and Baeten, Dominique and Van Den Bosch, Filip and Kruithof, Elli and Mielants, Herman and Veys, Eric},
  journal      = {Rheumatic diseases Clin. N. Am.},
  pages        = {463--479},
  title        = {Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation},
  volume       = {29},
  year         = {2003},
}